Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
about
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsThe Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast CancerMeta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
P2860
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Chemotherapy-associated treatm ...... y data from a phase III study.
@ast
Chemotherapy-associated treatm ...... y data from a phase III study.
@en
type
label
Chemotherapy-associated treatm ...... y data from a phase III study.
@ast
Chemotherapy-associated treatm ...... y data from a phase III study.
@en
prefLabel
Chemotherapy-associated treatm ...... y data from a phase III study.
@ast
Chemotherapy-associated treatm ...... y data from a phase III study.
@en
P2093
P2860
P1476
Chemotherapy-associated treatm ...... y data from a phase III study.
@en
P2093
Anton Buchner
Oleg A Gladkov
Peter Bias
Reiner Elsässer
Udo Müller
P2860
P2888
P304
P356
10.1007/S00520-015-2803-9
P577
2015-06-20T00:00:00Z